32.9 C
Saturday, May 15, 2021

Moderna Covid jab efficacy marginally drops to 90% in US trial

- Advertisement -

US okays Moderna Covid-19 vaccine as pandemic surge worsensNew York, Apr 14 (IANS): Updated results from an ongoing Phase 3 clinical trial in the US have shown Moderna’s Covid-19 vaccine to be 90 per cent effective against all cases of the disease, and greater than 95 per cent against severe cases.

While the updated cases show continued strong efficacy of the vaccine, the efficacy represents a marginal drop from an earlier figure of 94.1 per cent published in The New England Journal of Medicine in December.

The ongoing study involves more than 30,000 people across the US.

The new results are based on 900 adjudicated cases of Covid-19 as of April 9, Moderna said on Tuesday.

READ ALSO:  Scientists call for investigation into origins of Covid-19

The previous study was based on 185 cases.

The US-based biotechnology company also said that results from a preclinical study of its Covid-19 variant-specific vaccine candidates showed that the variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralising titers against SARS-CoV-2 variants of concern.

“The Moderna team continues to make important progress with our Covid-19 vaccine. We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase 2/3 study of our Covid-19 Vaccine in adolescents,” Stephane Bancel, Chief Executive Officer of Moderna, said in a statement.

“The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our Covid-19 vaccine as necessary until the pandemic is under control.”

READ ALSO:  Over 13L frontline workers provided online training to manage pandemic: Health Min
READ ALSO:  'Headache, dizziness before fever and cough may signal Covid-19'

Moderna has so far delivered approximately 132 million doses of its Covid-19 vaccine globally.

New preclinical data on the company’s variant-specific booster vaccine candidates have been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication, Moderna said.

These variant-specific vaccine candidates include mRNA-1273.351, which is more specifically targeted against the SARS-CoV-2 variant known as B.1.351 first identified in South Africa, and a multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273 (Moderna’s authorised vaccine against ancestral strains) and mRNA-1273.351 in a single vaccine.

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News


Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India